Highlights from the SNO 2020 virtual conference


The SNO 2020 virtual conference included many presentations on new and potential treatments, particularly for glioblastoma. The following three studies were particularly interesting, showing the promising advances that are being made.

Novel T cell-enabling therapies plus checkpoint inhibition in newly diagnosed glioblastoma

New data came from a study of a combination of vaccination for known tumor-associated antigens – elicited by synthetic DNA plasmids for hTERT, WT-1, and PSMA with synchronous IL-12 stimulation – with PD-L1 blockade using cemiplimab, in newly diagnosed glioblastoma (presentation LTBK-01).

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.